ArticleContemporary clinical trials communications2021

A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Miko Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.